AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers
Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 18, 2024 Category: Allergy & Immunology Tags: Pulmonary Medicine Source Type: news

AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
(Source: Reuters: Health)
Source: Reuters: Health - March 14, 2024 Category: Consumer Health News Source Type: news

AstraZeneca strikes $1 billion deal for rare-disease drug maker
AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2024 Category: Consumer Health News Source Type: news

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. (Source: World Pharma News)
Source: World Pharma News - March 14, 2024 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Mankind Pharma enters exclusive pact to distribute AstraZeneca's anti-asthma drug Symbicort in India
AstraZeneca Pharma India has partnered with Mankind Pharma to exclusively distribute its anti-asthma drug Symbicort in India. AstraZeneca will retain the intellectual property rights to Symbicort and continue as the marketing authorization holder. Symbicort, a top-selling product globally for AstraZeneca, recorded sales of around $2.4 billion in 2023. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 11, 2024 Category: Pharmaceuticals Source Type: news

When £17m isn’t enough: FTSE firms plead to pay bosses millions more
There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package, up from £15.3m a year earlier. The latest award brings to £137m the amount he has earned since joining…#astrazeneca #pascalsoriots #ftse #sundarpichai #alphabet #google #atlantic #andrewninian #smithnephew #namalnawana (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2024 Category: Consumer Health News Source Type: news

AstraZeneca bets on licencing deals, public-private partnerships for India growth
British-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, renal, and metabolic diseases, respiratory and immunology, and rare diseases. The company aims to expand access to its therapies through public-private partnerships, licensing deals, and tiered pricing. AstraZeneca's India business returned to growth in FY23 after a period of plateauing sales, driven by innovative molecules. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 8, 2024 Category: Pharmaceuticals Source Type: news

Poorly controlled asthma generates greenhouse gases equivalent to 124,000 UK homes
Poorly controlled asthma is contributing to more than 300,000 tons of greenhouse gas emissions in the UK every year, an analysis has suggested. Most of the carbon footprint comes from over-reliance on reliever inhalers, a study published in Thorax and carried out by Astra Zeneca found. Using health records of 236,506 people with asthma between 2008 and... Read moreThe post Poorly controlled asthma generates greenhouse gases equivalent to 124,000 UK homes appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - March 7, 2024 Category: Nursing Authors: Megan Ford Tags: Clinical Latest news Respiratory Source Type: news

AstraZeneca to Invest 650 Million Pounds in UK to Boost Pandemic Preparedness AstraZeneca to Invest 650 Million Pounds in UK to Boost Pandemic Preparedness
AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on...Reuters Health Information (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - March 6, 2024 Category: Infectious Diseases Tags: Public Health & Prevention Source Type: news

A quiet conspiracy is afoot to give FTSE 100 executives a pay rise
It seems the UK financial and corporate establishment is agreed. The London stock market is in a funk, with too many companies hopping off to re-list in New York. Therefore the UK executive class must be given US-style pay packages to keep ‘em loyal. That’s a slight exaggeration since, so far,…#astrazeneca #londonstockexchange #smithnephew #ftse #nt #davidschwimmer #juliahoggett #pascalsoriot #sherimccoy (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news

The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs highlighted that Europe's stock markets were dominated by this group of "internationally exposed quality growth…#paneuropean #goldmansachs #gsk #roche #asml #nestle #novartis #novonordisk #loreal #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news

Tagrisso With the Addition of Chemotherapy Approved in the US for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
19 February 2024 -- AstraZeneca’s Tagrisso has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2024 Category: Drugs & Pharmacology Source Type: news

Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer 19 February... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 19, 2024 Category: Drugs & Pharmacology Source Type: news

Largest Covid vaccine study ever finds shots are linked to small increased risk of neurological, blood and heart disorders - but they are still extremely rare
Covid vaccines made by Pfizer , Moderna , and AstraZeneca have been linked to a small but significant proportion of heart, blood, and neurological disorders. (Source: the Mail online | Health)
Source: the Mail online | Health - February 19, 2024 Category: Consumer Health News Source Type: news

We aren't anti-vaxxers, we just want justice for our loved ones who died after getting the AstraZeneca Covid vaccine
The AstraZeneca (AZ) Covid vaccine rollout was a huge success story. What's less well-known is that for a small number of desperately unlucky people in the UK it had a catastrophic effect. (Source: the Mail online | Health)
Source: the Mail online | Health - February 19, 2024 Category: Consumer Health News Source Type: news